| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 44,640 | 44,760 | 15:56 | |
| 43,880 | 43,960 | 15:43 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 44,365 | 1.100 | |||
| 44,360 | 222 | |||
| 44,355 | 197 | |||
| 44,255 | 750 | |||
| 44,215 | 290 | |||
| 44,205 | 52 | |||
| 44,200 | 1.100 | |||
| 44,145 | 193 | |||
| 44,085 | 193 | |||
| 44,075 | 753 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 58 | 43,940 | |||
| 280 | 43,935 | |||
| 560 | 43,930 | |||
| 193 | 43,920 | |||
| 293 | 43,900 | |||
| 1.100 | 43,810 | |||
| 150 | 43,800 | |||
| 1 | 43,775 | |||
| 26 | 43,705 | |||
| 5.500 | 43,700 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 8.161 | 0,594 | 4.850 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:39:47 | 43,670 | 136 |
| 15:38:34 | 43,350 | 360 |
| 15:38:34 | 43,350 | 200 |
| 15:36:34 | 43,155 | 280 |
| 15:36:34 | 43,175 | 159 |
| 15:35:06 | 43,130 | 128 |
| 15:34:21 | 43,245 | 193 |
| 15:34:18 | 43,200 | 133 |
| 15:32:33 | 43,420 | 750 |
| 15:32:33 | 43,425 | 179 |
| 15:32:08 | 43,605 | 125 |
| 15:30:00 | 44,345 | 140 |
| 15:30:00 | 44,635 | 16 |
| 15:22:25 | 44,520 | 56 |
| 15:21:25 | 44,520 | 19 |
| 15:19:45 | 44,500 | 45 |
| 15:19:45 | 44,520 | 125 |
| 15:03:20 | 44,470 | 191 |
| 15:03:20 | 44,470 | 9 |
| 15:03:16 | 44,280 | 2 |
| Tagesumsatz Xetra | -0,245 -0,56 % | 19.615 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MODERNA Aktie jetzt für 0€ handeln | |||||
| 14:50 | Moderna freut sich über eine Zulassungsempfehlung der EMA für einen Kombi-Impfstoff gegen Corona und Grippe | 205 | NTG24.de | Bei Corona-Impfstoffen war der US-Konzern Moderna noch ein Nachzügler. Anders scheint es nun bei Kombi-Impfstoffen zu laufen, die gleichzeitig vor Corona und der Grippe schützen. Dafür gibt es bisher... ► Artikel lesen | |
| Fr | Moderna's combination flu, COVID shot wins over European drug regulators | 15 | BioPharma Dive | ||
| Fr | Moderna: Kombi-Impfung für Grippe und Covid erhält Zulassung | 468 | Der Aktionär | Gute Nachrichten für Moderna: Die EU-Arzneimittelbehörde EMA hat grünes Licht gegeben für den ersten Kombi-Impfstoff gegen Corona und Grippe. Der Wirkstoff solle für Menschen ab 50 Jahren zugelassen... ► Artikel lesen | |
| Fr | After CHMP nod, Moderna CEO applauds EU's 'rigorous scientific review' | 6 | FiercePharma | ||
| Fr | mCombriax von Moderna: Erster Kombiimpfstoff gegen Covid und Grippe kommt | 6 | Pharmazeutische Zeitung |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:06 | NovoCure's Optune Lua Secures Japan Health Ministry's Reimbursement Approval For NSCLC Patients | AFX News | WASHINGTON (dpa-AFX) - NovoCure Limited (NVCR), Monday announced that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua, authorized for use in adult patients... ► Artikel lesen | |
| 14:38 | Ainos, Inc.: Ainos Issues Shareholder Letter on Phased AI Nose Deployment of Up to 20,000 Systems and Scalable Recurring Revenue Opportunity | ACCESS Newswire | HOUSTON, TEXAS / ACCESS Newswire / March 2, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today issued the following letter from Chairman, President and Chief Executive Officer... ► Artikel lesen | |
| 14:10 | Evaxion to announce business update and full year 2025 financial results on March 5, 2026 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, will provide a business... ► Artikel lesen | |
| 14:26 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team | ACCESS Newswire | Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNSNewly formed executive team is committed to execution and company... ► Artikel lesen | |
| 14:06 | UroGen Pharma Ltd.: UroGen Announces ZUSDURI Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results | GlobeNewswire (Europe) | Commercial launch is on-track for ZUSDURI, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales... ► Artikel lesen |